718 results on '"El‐Agnaf, Omar"'
Search Results
2. Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease
3. Production of α-Synuclein Fibrillar-Specific scFv from Inclusion Bodies
4. Uncovering a neurological protein signature for severe COVID-19
5. Cross-sectional proteomic expression in Parkinson's disease-related proteins in drug-naïve patients vs healthy controls with longitudinal clinical follow-up
6. Retraction Notice to: Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson’s Disease and Other Brain Disorders
7. Retraction Notice to: Corrigendum to “Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson’s Disease and Other Brain Disorders”
8. Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease
9. Untargeted Metabolomic Profiling Reveals Differentially Expressed Serum Metabolites and Pathways in Type 2 Diabetes Patients with and without Cognitive Decline: A Cross-Sectional Study
10. Structural insights into the unique recognition module between α‐synuclein peptide and nanobody
11. Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein
12. Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy
13. Diagnosis and management of dementia with Lewy bodies
14. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
15. Cross-sectional proteomic expression in Parkinson's disease-related proteins in drug-naïve patients vs healthy controls with longitudinal clinical follow-up
16. High-throughput autoantibody screening identifies differentially abundant autoantibodies in autism spectrum disorder
17. Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
18. Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans
19. CSF and blood biomarkers for Parkinson's disease
20. Quantification of brain-derived extracellular vesicles in plasma as a biomarker to diagnose Parkinson's and related diseases
21. IgG index of cerebrospinal fluid can reflect pathophysiology associated with Lewy bodies in Parkinson's disease
22. Auto-immunoproteomics analysis of COVID-19 ICU patients revealed increased levels of autoantibodies related to the male reproductive system
23. Alpha-Synuclein in Cerebrospinal Fluid
24. Lewy body pathology is more prevalent in older individuals with mitochondrial disease than controls
25. Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts
26. Corrigendum to “ Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy Body Disease” [Neurobiology of Disease127 (2019) 163–177]
27. Expansion of the Parkinson disease-associated SNCA- Rep1 allele upregulates human α-synuclein in transgenic mouse brain
28. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain.
29. Blood-Based Proteomic Profiling Identifies Potential Biomarker Candidates and Pathogenic Pathways in Dementia
30. Blood Proteomics Analysis Reveals Potential Biomarkers and Convergent Dysregulated Pathways in Autism Spectrum Disorder: A Pilot Study
31. Complex I reductions in the nucleus basalis of Meynert in Lewy body dementia: the role of Lewy bodies
32. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity
33. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
34. The immune system in Parkinson's disease: From biology to diagnosis and therapeutic targets
35. Studies on peptides related to Alzheimer amyloid
36. Plasma-derived therapy: can the survivors of COVID-19 help the defenseless?
37. Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy
38. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson’s disease
39. Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid
40. Circulating MicroRNA Profiling Identifies Distinct MicroRNA Signatures in Acute Ischemic Stroke and Transient Ischemic Attack Patients
41. Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers
42. Inhibition of α-Synuclein Seeding-Dependent Aggregation by ssDNA Aptamers Specific to C-Terminally Truncated α-Synuclein Fibrils
43. Identification of distinct circulating microRNAs in acute ischemic stroke patients with type 2 diabetes mellitus
44. Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects
45. α-Synuclein Aggregation and Modulating Factors
46. Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
47. Immune-related biomarkers for Parkinson's disease
48. Gene-Based Therapeutics for Parkinson’s Disease
49. Alpha-Synuclein in Cerebrospinal Fluid
50. Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.